{
    "relation": [
        [
            "Company",
            "Abbott Laboratories",
            "Biogen Inc.",
            "Celgene Corp.",
            "AstraZeneca PLC ADR",
            "Bristol-Myers Squibb Co.",
            "Baxter International Inc.",
            "Gilead Sciences Inc.",
            "Teva Pharmaceutical Industries Ltd. ADR",
            "Eli Lilly & Co."
        ],
        [
            "Last",
            "50.94",
            "319.93",
            "135.42",
            "32.81",
            "64.66",
            "38.09",
            "113.07",
            "71.41",
            "85.68"
        ],
        [
            "% Change",
            "+0.49%",
            "+3.39%",
            "+2.16%",
            "+0.31%",
            "+0.56%",
            "+1.03%",
            "+2.29%",
            "-0.82%",
            "+1.82%"
        ]
    ],
    "pageTitle": "LLY Key Statistics - Eli Lilly & Co. Financial Ratios - MarketWatch",
    "title": "",
    "url": "http://www.marketwatch.com/investing/stock/LLY/profile",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 1,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042982745.46/warc/CC-MAIN-20150728002302-00220-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 576454203,
    "recordOffset": 576422567,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{3944=1:42 p.m. July 23, 2015, 10320=Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16, 4139=Shire Lifts 2015 Guidance On Strong Drug Pipeline, 10572=8:01 a.m. July 27, 2015, 18158=12:23 p.m. July 15, 2015, 12517=7:43 a.m. Today7:43 a.m. July 28, 2015, 20077=9:39 a.m. July 22, 2015, 4391=3:04 p.m. July 23, 2015, 16654=5:56 p.m. July 7, 2015, 4877=3:10 p.m. July 23, 2015, 13976=9:42 a.m. June 12, 2015, 15507=12:34 p.m. June 23, 2015, 6949=Lilly (Eli) (LLY) Earnings Report: Q2 2015 Conference Call Transcript, 18494=3:17 p.m. July 15, 2015, 32546=Eli Lilly & Co. discovers, develops, manufactures and sells pharmaceutical products. The company operates through the following business segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Eli Lilly was founded by Colonel Eli Lilly on May 1876 and is headquartered in Indianapolis, IN., 8170=8:12 a.m. July 24, 2015, 8685=12:26 p.m. July 24, 2015, 20432=11:40 a.m. July 22, 2015, 15908=6:05 a.m. June 25, 2015, 5337=4:00 p.m. July 23, 2015, 13047=12:57 p.m. Today12:57 p.m. July 28, 2015, 2840=1 3172762000, 6696=5:17 p.m. July 23, 2015, 16320=9:34 a.m. June 25, 2015, 15108=12:10 p.m. June 23, 2015, 5087=Dow Turns Negative for 2015 as Losses Accelerate, 12022=11:51 a.m. July 27, 2015, 7457=Eli Lilly's (LLY) CEO John Lechleiter on Q2 2015 Results - Earnings Call Transcript, 19309=7:23 a.m. July 22, 2015, 9141=10:52 a.m. July 26, 2015, 5770=4:07 p.m. July 23, 2015, 9544=2:35 p.m. July 26, 2015, 18910=2:46 a.m. July 21, 2015, 11070=8:17 a.m. July 27, 2015, 7201=7:11 p.m. July 23, 2015, 6250=4:50 p.m. July 23, 2015, 11739=Lilly to continue late-stage evacetrapib study; results expected mid-2016, 20818=6:58 a.m. July 23, 2015, 7739=3:58 a.m. July 24, 2015, 38300=Jul 28, 2015, 5:48 p.m., 17449=12:22 p.m. July 15, 2015, 14720=9:58 a.m. June 19, 2015, 14329=2:38 p.m. June 12, 2015, 21221=6:58 a.m. July 27, 2015, 19746=8:03 a.m. July 22, 2015, 2431=12/2015, 17110=1:35 p.m. July 9, 2015, 11497=9:02 a.m. July 27, 2015, 9949=7:01 a.m. July 27, 2015}",
    "TableContextTimeStampAfterTable": "{10327=Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019, 9496=Global Neurodegenerative Diseases Market 2015-2019, 35455=Copyright \u00a9 2015 MarketWatch, Inc. All rights reserved. By using this site, you agree to the Terms of Service, Privacy Policy and Cookie Policy., 5699=8:33 a.m. July 22, 2015, 13269=2:00 a.m. June 29, 2015, 11170=Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025, 12786=8:00 a.m. June 29, 2015, 12064=Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement, 4010=8:00 a.m. July 27, 2015, 10513=4:14 p.m. July 6, 2015, 8210=9:25 a.m. July 20, 2015, 4521=12:04 p.m. July 23, 2015, 10920=3:39 p.m. July 6, 2015, 9245=3:00 p.m. July 14, 2015, 11813=12:00 p.m. July 6, 2015, 8711=7:02 a.m. July 17, 2015, 9648=7:28 p.m. July 13, 2015, 6708=7:00 a.m. July 22, 2015, 10077=1:55 p.m. July 9, 2015, 4983=6:32 a.m. July 23, 2015, 6138=8:00 a.m. July 22, 2015, 11618=Next-Generation Biologics: R&D, Industry and Market Forecasts 2015-2025, 12304=1:30 p.m. July 1, 2015, 11368=1:12 p.m. July 6, 2015, 7165=9:05 a.m. July 21, 2015, 7644=11:00 a.m. July 20, 2015, 10763=Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025}",
    "textBeforeTable": "Key Competitors }); }); } return $node.text(); return text.replace(/%/, \"\"); if (text && text.length > 0) var text = $node.find(\"p.bgPercentChange\").text(); var $node = $(node); textExtraction: function(node) { cssHeader: \"indexHeader\", sortList: [[2,1]], //headers: { 4: { sorter: false } }, $(\"#companyCompetitors\").tablesorter({ }); }); return message.b.y != \"normal\"; $(this).data(\"bgfilter\", function(message) { quotes.each(function() { }); $(\"#indexComponents\").trigger(\"update\"); quotes.bind(\"bgTick\", function() { var quotes = $(\"#companyCompetitors .bgQuote\") $(function() { })(); document.write(''); var mnSrc = (isSSL ? 'https:' : 'http:') + '//contextual.media.net/nmedianet.js?cid=8CU6CD37D' + (isSSL ? '&https=1' : ''); var isSSL = 'https:' == document.location.protocol; (function() { medianet_versionId = \"111299\"; medianet_crid = \"266203568\"; medianet_height = \"204\"; medianet_width = \"377\";",
    "textAfterTable": "/news/pressrelease/company/us/lly Press Releases on LLY Lilly Provides Update on Evacetrapib Phase 3 Trial 8:00 a.m. July 27, 2015 - PR Newswire - PRF Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew 12:04 p.m. July 23, 2015 - PR Newswire - PRF Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center 6:32 a.m. July 23, 2015 - PR Newswire - PRF Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges 8:33 a.m. July 22, 2015 - PR Newswire - PRF Proteon Therapeutics Appoints Scott Canute to Its Board of Directors 8:00 a.m. July 22, 2015 - GlobeNewswire Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease 7:00 a.m. July 22, 2015 - PR Newswire - PRF PharmaCyte",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}